Einārs Loža

590 total citations
23 papers, 436 citations indexed

About

Einārs Loža is a scholar working on Molecular Biology, Organic Chemistry and Clinical Biochemistry. According to data from OpenAlex, Einārs Loža has authored 23 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Organic Chemistry and 5 papers in Clinical Biochemistry. Recurrent topics in Einārs Loža's work include Histone Deacetylase Inhibitors Research (6 papers), Metabolism and Genetic Disorders (5 papers) and Biochemical and Molecular Research (3 papers). Einārs Loža is often cited by papers focused on Histone Deacetylase Inhibitors Research (6 papers), Metabolism and Genetic Disorders (5 papers) and Biochemical and Molecular Research (3 papers). Einārs Loža collaborates with scholars based in Latvia, Denmark and United States. Einārs Loža's co-authors include Solveiga Grı̄nberga, Maija Dambrova, Marina Makrecka‐Kuka, Edgars Liepinsh, Janis Kuka, Osvalds Pugovičs, Ivars Kalvinsh, Helena Cirule, Jānis Liepiņš and Reinis Vilšķe̅rsts and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Journal of Chromatography A.

In The Last Decade

Einārs Loža

23 papers receiving 429 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Einārs Loža Latvia 13 283 85 63 62 60 23 436
Michelle K. Dennehy United States 7 306 1.1× 152 1.8× 23 0.4× 81 1.3× 40 0.7× 10 582
Orrette R. Wauchope United States 13 259 0.9× 31 0.4× 81 1.3× 24 0.4× 106 1.8× 20 447
Silvia Pace Italy 15 250 0.9× 34 0.4× 47 0.7× 143 2.3× 45 0.8× 33 506
Huachuan Cao United States 16 739 2.6× 75 0.9× 49 0.8× 74 1.2× 64 1.1× 20 940
Bhavani Sangras United States 10 712 2.5× 107 1.3× 26 0.4× 107 1.7× 74 1.2× 10 1.0k
Michael W. Voice United Kingdom 12 276 1.0× 71 0.8× 21 0.3× 59 1.0× 50 0.8× 21 710
Larissa M. Balogh United States 14 247 0.9× 37 0.4× 27 0.4× 279 4.5× 38 0.6× 15 632
Sarala Kodukula United States 8 247 0.9× 133 1.6× 19 0.3× 49 0.8× 22 0.4× 10 392
B. Kevin Park United Kingdom 13 151 0.5× 26 0.3× 31 0.5× 93 1.5× 28 0.5× 15 485
Kazuhiro Kojima Japan 12 150 0.5× 35 0.4× 35 0.6× 46 0.7× 46 0.8× 41 440

Countries citing papers authored by Einārs Loža

Since Specialization
Citations

This map shows the geographic impact of Einārs Loža's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Einārs Loža with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Einārs Loža more than expected).

Fields of papers citing papers by Einārs Loža

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Einārs Loža. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Einārs Loža. The network helps show where Einārs Loža may publish in the future.

Co-authorship network of co-authors of Einārs Loža

This figure shows the co-authorship network connecting the top 25 collaborators of Einārs Loža. A scholar is included among the top collaborators of Einārs Loža based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Einārs Loža. Einārs Loža is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Sha, Bo Lundgren, Katharina Klöditz, et al.. (2024). Design, synthesis, and in vitro biological evaluation of meta-sulfonamidobenzamide-based antibacterial LpxH inhibitors. European Journal of Medicinal Chemistry. 278. 116790–116790. 1 indexed citations
2.
Loža, Einārs, et al.. (2021). Aziridine-2-carboxylic acid derivatives and its open-ring isomers as a novel PDIA1 inhibitors. Chemistry of Heterocyclic Compounds. 57(11). 1086–1106. 2 indexed citations
3.
Liao, Chengheng, Yang Zhang, Cheng Fan, et al.. (2020). Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. Cancer Discovery. 10(11). 1706–1721. 49 indexed citations
4.
Loža, Einārs, Mārtiņš Katkevičs, Victoria Ryabova, et al.. (2020). Structure-activity relationship studies on the inhibition of the bacterial translation of novel Odilorhabdins analogues. Bioorganic & Medicinal Chemistry. 28(11). 115469–115469. 5 indexed citations
5.
Loža, Einārs, et al.. (2018). Synthesis of 2-substituted oxazoloquinazolinones. Chemistry of Heterocyclic Compounds. 54(11). 1070–1074. 2 indexed citations
6.
Charlton, M., Adélaïde Saint-Léger, Arya Gupta, et al.. (2018). N-Leucinyl Benzenesulfonamides as Structurally Simplified Leucyl-tRNA Synthetase Inhibitors. ACS Medicinal Chemistry Letters. 9(2). 84–88. 17 indexed citations
7.
Дубурс, Г., et al.. (2017). Synthesis and evaluation of (E)-2-(5-phenylpent-2-en-4-ynamido)cyclohex-1-ene-1-carboxylate derivatives as HCA2 receptor agonists. Bioorganic & Medicinal Chemistry. 25(16). 4314–4329. 3 indexed citations
8.
Björkling, Fredrik, et al.. (2015). The synthesis of some sulfonamides based on 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine. Chemistry of Heterocyclic Compounds. 51(7). 658–663. 2 indexed citations
9.
Kuka, Janis, Edgars Liepinsh, Marina Makrecka‐Kuka, et al.. (2014). Suppression of intestinal microbiota-dependent production of pro-atherogenic trimethylamine N-oxide by shifting L-carnitine microbial degradation. Life Sciences. 117(2). 84–92. 75 indexed citations
10.
Liepinsh, Edgars, Marina Makrecka‐Kuka, Janis Kuka, et al.. (2014). Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availability of l-carnitine and to reduce myocardial infarct size. Pharmacological Research. 85. 33–38. 16 indexed citations
11.
Liepinsh, Edgars, Marina Makrecka‐Kuka, Janis Kuka, et al.. (2014). Inhibition of L‐carnitine biosynthesis and transport by methyl‐γ‐butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction. British Journal of Pharmacology. 172(5). 1319–1332. 35 indexed citations
12.
Tārs, Kaspars, Ja̅nis Leita̅ns, Andris Kazāks, et al.. (2014). Targeting Carnitine Biosynthesis: Discovery of New Inhibitors against γ-Butyrobetaine Hydroxylase. Journal of Medicinal Chemistry. 57(6). 2213–2236. 37 indexed citations
13.
Дубурс, Г., et al.. (2014). Synthesis and evaluation of (E)-2-(acrylamido)cyclohex-1-enecarboxylic acid derivatives as HCA1, HCA2, and HCA3 receptor agonists. Bioorganic & Medicinal Chemistry. 22(14). 3654–3669. 9 indexed citations
14.
Kiesel, Brian F., Robert A. Parise, Jette Tjørnelund, et al.. (2013). LC–MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 81-82. 89–98. 17 indexed citations
15.
Christensen, Mette Krogh, Kamille Dumong Erichsen, Uffe H. Olesen, et al.. (2013). Nicotinamide Phosphoribosyltransferase Inhibitors, Design, Preparation, and Structure–Activity Relationship. Journal of Medicinal Chemistry. 56(22). 9071–9088. 30 indexed citations
16.
Kelly, John M., Martin C. Taylor, David Horn, et al.. (2012). Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei. Bioorganic & Medicinal Chemistry Letters. 22(5). 1886–1890. 21 indexed citations
17.
Kiesel, Brian F., Robert A. Parise, Jette Tjørnelund, et al.. (2012). Abstract 759: Quantitation of the HDAC inhibitor belinostat (PXD-101) and metabolites in human plasma by a novel LC-MS/MS assay.. Cancer Research. 72(8_Supplement). 759–759. 1 indexed citations
18.
Loža, Einārs, et al.. (2011). Synthesis of 2-quinolinecarboxamide derivatives as potential HDAC inhibitors. Chemistry of Heterocyclic Compounds. 47(6). 719–727. 1 indexed citations
19.
Loža, Einārs, Ivars Kalvinsh, Paul W. Finn, et al.. (2008). Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR. European Journal of Medicinal Chemistry. 44(3). 1067–1085. 26 indexed citations
20.
Finn, Paul W., Ruth Hollinshead, Nagma Khan, et al.. (2005). Novel Sulfonamide Derivatives as Inhibitors of Histone Deacetylase. Helvetica Chimica Acta. 88(7). 1630–1657. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle K. Dennehy Breakdown of academic impact, for papers by Orrette R. Wauchope Breakdown of academic impact, for papers by Silvia Pace Breakdown of academic impact, for papers by Huachuan Cao Breakdown of academic impact, for papers by Bhavani Sangras Breakdown of academic impact, for papers by Michael W. Voice Breakdown of academic impact, for papers by Larissa M. Balogh Breakdown of academic impact, for papers by Sarala Kodukula Breakdown of academic impact, for papers by B. Kevin Park Breakdown of academic impact, for papers by Kazuhiro Kojima
Rankless by CCL
2026